Novartis AG (NVS)
110.59
+1.24
(+1.13%)
USD |
NYSE |
Nov 04, 13:21
Novartis Debt to Equity Ratio: 0.6999 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.6999 |
| June 30, 2024 | 0.6516 |
| March 31, 2024 | 0.6435 |
| December 31, 2023 | 0.5254 |
| September 30, 2023 | 0.6164 |
| June 30, 2023 | 0.512 |
| March 31, 2023 | 0.5256 |
| December 31, 2022 | 0.4402 |
| September 30, 2022 | 0.4404 |
| June 30, 2022 | 0.4653 |
| March 31, 2022 | 0.4792 |
| December 31, 2021 | 0.4306 |
| September 30, 2021 | 0.5714 |
| June 30, 2021 | 0.6273 |
| March 31, 2021 | 0.7108 |
| December 31, 2020 | 0.6334 |
| September 30, 2020 | 0.6649 |
| June 30, 2020 | 0.6101 |
| March 31, 2020 | 0.6828 |
| December 31, 2019 | 0.4903 |
| September 30, 2019 | 0.5359 |
| June 30, 2019 | 0.5488 |
| March 31, 2019 | 0.6067 |
| December 31, 2018 | 0.4082 |
| September 30, 2018 | 0.4078 |
| Date | Value |
|---|---|
| June 30, 2018 | 0.4212 |
| March 31, 2018 | 0.4798 |
| December 31, 2017 | 0.3833 |
| September 30, 2017 | 0.4171 |
| June 30, 2017 | 0.4371 |
| March 31, 2017 | 0.4625 |
| December 31, 2016 | 0.3165 |
| September 30, 2016 | 0.3543 |
| June 30, 2016 | 0.3639 |
| March 31, 2016 | 0.3912 |
| December 31, 2015 | 0.2843 |
| September 30, 2015 | 0.2959 |
| June 30, 2015 | 0.2955 |
| March 31, 2015 | 0.3288 |
| December 31, 2014 | 0.2877 |
| September 30, 2014 | 0.2748 |
| June 30, 2014 | 0.2903 |
| March 31, 2014 | 0.3021 |
| December 31, 2013 | 0.241 |
| September 30, 2013 | 0.2606 |
| June 30, 2013 | 0.2716 |
| March 31, 2013 | 0.3125 |
| December 31, 2012 | 0.2853 |
| September 30, 2012 | 0.3107 |
| June 30, 2012 | 0.3529 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.4306
Minimum
Dec 2021
0.7108
Maximum
Mar 2021
0.5711
Average
0.5907
Median
Debt to Equity Ratio Benchmarks
| Amgen Inc | 8.024 |
| AstraZeneca PLC | 0.8173 |
| Johnson & Johnson | 0.5096 |
| Eli Lilly and Co | 2.185 |
| Merck & Co Inc | 0.8671 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 103.52B |
| Total Liabilities (Quarterly) | 60.08B |
| Shareholders Equity (Quarterly) | 43.32B |
| Current Ratio | 1.111 |
| Net Debt Paydown Yield | -0.33% |